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We report a case of ulcerative colitis (UC) and recurrent Clostridium diﬃcile infection (CDI) where the patient was on immun-
omodulatory therapy and had successful CDI eradication after fecal transplantation. This is the ﬁrst case report in the literature
documenting successful C. diﬃcile eradication in an immunosuppressed patient. We feel that fecal transplantation should be
studied as a treatment option in these patients.
1.Introduction
Clostridium diﬃcile has emerged as a major cause of anti-
biotic-associated diarrhea [1]. The treatment of recurrent
Clostridium diﬃcile infection (CDI) has not been standard-
ized; however, fecal bacteriotherapy has demonstrated an
average success rate of 92% as shown in a recent systemic re-
view [2].
Association between CDI and ulcerative colitis (UC),
which is an inﬂammatory bowel disease with unknown eti-
ology, has been reported [3, 4]; however, fecal bacteriother-
apy has been performed particularly in few patients with
inﬂammatory bowel disease and none while the patient is on
immunosuppression.
2. Case Presentation
The patient is a 51-year-old man with a 13-year history of
UC, who experienced frequent exacerbations of his disease
proven by colonoscopies (Figure 1) and subsequent biopsies.
Some of the ﬂares were severe and some of them were mild
to moderate. Early in the course of the disease, the patient
was treated with three doses of inﬂiximab; however, this
treatment was terminated based on the patient’s decision.
He did not tolerate aminosalicylic acid derivatives due to an
allergicreaction;therefore,azathioprinewasusedchronically
to suppress the UC in addition to episodic oral or rectal
steroids to treat the breakthrough ﬂares. The azathioprine
dose ranged mainly between 100–125mg daily.
Most exacerbations were related to CDI, which was diag-
nosed by testing the stool for Clostridium diﬃcile toxin (PCR
was used once to establish the diagnosis). CDI recurred 4
times in the last few years, which made it more diﬃcult to
control the UC. The patient was complaining of continuous
weakness and fatigue along with the diarrhea. CDI episodes
were treated with oral vancomycin. The eradication of CDI
allowed better control of his UC; therefore, he was commit-
ted to long-term suppressive therapy with oral once-daily
vancomycin.
Fecal transplantation was considered in this patient de-
spite the uniqueness of this case. The risks and beneﬁts were
discussed with the patient. His blood work prior to the pro-
cedure revealed: white blood count of 5.7k/uL, hemoglobin
of 15.5mg/dL, platelets of 258k/uL, Albumin of 4.2mg/dL,
and creatinine of 1.1mg/dL. The donor’s stool specimen was
obtained from the wife who tested negative for Clostridium2 Case Reports in Infectious Diseases
Figure 1: Picture of the patient’s colon taken during colonoscopy.
The image reveals diﬀuse inﬂammation with submucosal hemor-
rhage.
diﬃcile PCR in the stool. Also, the wife serology was negative
for HIV and hepatitis (hepatitis A antibodies, hepatitis B
surface antigen, hepatitis B core antibodies, and hepatitis
C antibodies). Oral vancomycin was discontinued 24 hours
before the transplantation. The stool suspension was pre-
pared according to standard protocols [5]. Warm water was
added to 300mL of the donor’s stool, and the sample was
instilled via colonoscope without complications. Afterwards,
the patient remained symptom-free for 8 months and was
able to stop oral vancomycin without CDI recurrence to
date. The procedure was not associated with side eﬀects
despite the fact that it was done while the patient was
on an immunomodulator. The patient was aware of the
unusual nature of his circumstance and was anxious to have
this information available for other patients with similar
problem.
3. Discussion
Treatment of recurrent CDI with vancomycin and metron-
idazole has not always been successful. Case reports of fecal
bacteriotherapy have reported a high rate of C. diﬃcile
eradication based on the fact that restoration of the normal
colonic ﬂora helps to eradicate Clostridium diﬃcile [6]. The
experience with this evolving therapy is limited but a recent
case-series of 100 patients (without UC) showed 90% cure
rate associated with fecal transplantation [7].
ClinicaloutcomescanbeworsewhenCDIcoincideswith
UC ﬂares compared to non-CDI-associated ﬂares increasing
the rate of surgery [8], length of hospital stay and, mortality
[9].
Fecalbacteriotherapyhasbeenrecentlyusedforthetreat-
ment of relapsing UC in selected patients. That was dem-
onstrated in a case-series of 6 patients with conﬁrmed UC
who suﬀered severe recurrent bouts of UC but experienced
improvement in some symptoms by 1 week after fecal trans-
plantation and complete remission of UC by 4 months after
therapy [10]. Nevertheless, this therapy has not been used
for recurrent CDI in UC patients on immunomodulatory
therapy.
Our patient hadrecurrent UCﬂaresassociated with CDI,
which mandated using oral vancomycin to prevent recur-
rence. The patient was interested in a long-term cure of CDI
through fecal bacteriotherapy. It was a challenge to perform
this procedure in this patient since he was on azathioprine
but that did not aﬀect the outcome. Both CDI and UC sub-
sided and the patient’s fatigue resolved.
This is the ﬁrst report of bacteriotherapy using a fecal
enema in a patient with UC and chronic CDI on immun-
omodulatory therapy. The observation made from our case
suggests that fecal bacteriotherapy might be safe in CDI
patients with UC on immunosuppression. Furthermore, the
safety proﬁle needs to be evaluated further.
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